That is entirely up to the FDA. Argos is scheduled to release interim results of its current cancer treatment sometime around late April or early May. Depending on those results, the FDA might decided to accelerate approval of that treatment since the form of cancer it addresses moves very quickly, but I don’t see how approval could possibly happen before those results are known. However, regardless of if/when final approval actually occurs, encouraging test results should be sufficient to get the stock moving up since the potential market for its treatment is so large.

While TransEnterix has an interesting device, its financial statement is in pretty bad shape. Recently some short sellers have begun circling the stock (example: http://finance.yahoo.com/news/transenterix-moving-down-streetsweeper-calls-183109163.html), so I don’t know if can survive the onslaught.

Yes, ARGS is the “alpha cell” stock mentioned in the Special report, which you can find under the Resources tab at the top of this page (http://www.investingdaily.com/res/reports/term1y/STI-One_Little_Shot_to_Kill_Cancer_Dead-27x_Your_Money_on_the_Alpha_Cells_Discovery.pdf). No idea when the approval date will be since that is entirely up to the FDA, but we suspect a good interim report, expected in late April or early May – might induce them to accelerate the timeline for approval since the form of cancer it treats is so fatal.

If you are a gambler NWBO might be worth a roll of the dice, but at this point it appears its most recent trial is not going well. Last week’s Forbes article on it captures the situation pretty well: http://www.forbes.com/sites/kenkam/2016/03/23/northwest-bio-is-down-but-not-out/?utm_campaign=yahootix&partner=yahootix#60e84c65596e. Thank you.

ARGS. Here’s a link to the special report on it: http://www.investingdaily.com/res/reports/term1y/STI-One_Little_Shot_to_Kill_Cancer_Dead-27x_Your_Money_on_the_Alpha_Cells_Discovery.pdf.

Yes, LSCC is still a hold, and I will issue an alert if it is changed to a buy or a sell. I don’t see any news either, and no chatter on the message boards yet. Trading volume is average so it does not appear that one of its institutional holders is bailing out. Perhaps somebody is shorting the stock, but even that doesn’t make much sense given how close it is support. May be just a temporary imbalance between buy and sell orders, but I’ll keep an eye on it.

Hi Hector. Yesterday this article from Zacks appeared on Yahoo Finance about Zacks, which drew a lot of attention to the company: http://finance.yahoo.com/news/surging-earnings-estimates-signal-good-124412882.html. And other advisory services are beginning to notice it now, so demand for shares is surging. I have no idea what they know or don’t know, but clearly the expectation is for good news soon.

I am planning to buy some shares today. The stock is down over 10%. Is the FDA making the decision on 4-30-16 or have they changed the date? I haven’t seen any alerts or update regarding this. ARGS was the reason I subscribed to Smart Tech Investor. I would appreciate a reply before the market closes today so I can make a decision whether to buy the stock or not. Thanks.

Hi Ernest. We’re saying FDA may feel compelled to accelerate approval after the interim test results have been released, which could happen anytime after 4/30. Since those results are not yet known, the stock is reacting to what is known – the sudden departure of the company’s COO, and layoffs at its lab, which we discussed in the most recent issue. Thank you.

Hi Hector. Since our thesis for owning ARGS is that the interim test results, which could be released any week now, may compel accelerated FDA approval, buying it now before those results have been made public is our recommendation. Thank you.